Ed Schuuring

Professor, senior clinical scientist in molecular pathology, University Medical Center Groningen, Groningen, The Netherland

Three decades his research focuses on the identification of prognostic/predictive epigenetic and molecular markers for clinical outcome, response to chemo-radiotherapy, gene-targeted therapy and treatment-resistance in lung, GIST, Head&Neck cancer, as well as methylation-markers for the early detection of cervical cancer in scrapings. More recently his interest expanded to investigate and implement plasma ctDNA as a bloodborne-based molecular tool for the early cancer detection and classification for treatment-decision-making, and to predict MRD and response to targeted and immuno-therapy in patients with NEN/NET, NSCLC and GIST. As a CSMP he is active member in the UMCG Molecular Tumor Board and involved in harmonisation and standardisation of 8 Dutch MTBs. He is heading the laboratory of Molecular Pathology offering the latest innovative methods for treatment-decision-making in the region North-Netherlands.

He is a senior member of the Dutch Society of Pathology, PATH, COIN, AACR, AMP, ESP, ASCO, ELBS, among others, and consultant in (inter)national committees and advisory boards on Molecular Pathology, the organisation of international proficiency mutation testing in lung tissue biopsies and plasma ctDNA, and co-authored various international guidelines on Molecular Pathology. He graduated in Medical Biology in 1985 (Cum Laude) and his PhD in 1993 in Molecular Biology (University of Amsterdam). He worked as a staff clinical scientist in Molecular Pathology at LUMC (1991-2000) and UMCG (2001-now). He co-authored >300 publications.

Scroll to Top